Worldwide: Actavis v Eli Lilly: The Doctrine Of Equivalents In The UK, France And Germany

In view of the UK Supreme Court's judgment in Actavis v Eli Lilly, when will an 'equivalent' infringe as an immaterial variant? How does this compare with the law regarding equivalents in France and Germany? And would a court in France or Germany reach the same conclusion as Lord Neuberger?

In a landmark decision (Actavis v Eli Lilly), the UK Supreme Court has re-steered the law of patent infringement in the UK, stating that there is a doctrine of equivalents. As explained in our introductory article on the decision, Lord Neuberger, stated ([54]):

...a problem of infringement is best approached by addressing two issues, each of which is to be considered through the eyes of the notional addressee of the patent in suit, i.e. the person skilled in the relevant art. Those issues are: (i) does the variant infringe any of the claims as a matter of normal interpretation; and, if not, (ii) does the variant nonetheless infringe because it varies from the invention in a way or ways which is or are immaterial? If the answer to either issue is "yes", there is an infringement; otherwise, there is not.

What exactly does this mean?

Limb (i) is considered in our article titled Actavis v Eli Lilly - What is "normal interpretation"?

In this article, we consider limb (ii), specifically, how does the Supreme Court suggest that a question of infringement by so-called equivalence be assessed? We also consider how this UK doctrine of equivalents compares with the law regarding equivalents in France and Germany, and consider whether the courts in France and Germany would have reached the same conclusion as Lord Neuberger.

The law in the UK

Limb (ii) is not a question of construction

After equating the meaning of the words "construction" and "interpretation" (paragraph 53), Lord Neuberger said of limb (ii) (also referred to as "issue (ii)"):

"...so long as the issue [of infringement] is treated as one of interpretation, it will lead to a risk of wrong results in patent infringement cases and it will also lead to a risk of confusing the law relating to the interpretation of documents. In my opinion, issue (ii) involves not merely identifying what the words of a claim would mean in their context to the notional addressee, but also considering the extent if any to which the scope of protection afforded by the claim should extend beyond that meaning. As Sir Hugh Laddie wrote in his instructive article Kirin-Amgen - The End of Equivalents in England? (2009) 40 IIC 3, para 68, "[t]he Protocol is not concerned with the rules of construction of claims" but with "determining the scope of protection".

What is it that makes a variation "immaterial"?

When considering what makes a variation "immaterial", Lord Neuberger considered that the three questions formulated by Hoffmann J (as he then was) in Improver v Remington  [1990] FSR 181 provide helpful assistance but needed some reformulation. The reformulated questions, and Lord Neuberger's key reasoning in respect of them, are discussed below.

The first question

"Notwithstanding that it is not within the literal meaning of the relevant claim(s) of the patent, does the variant achieve substantially the same result in substantially the same way as the invention, i.e. the inventive concept revealed by the patent?"

Lord Neuberger said that the emphasis here is on how "the invention" works. The court should focus on the "the problem underlying the invention", "the inventive core", or "the inventive concept" as it has been variously termed in other jurisdictions.

Compared with the original first Improver question, Lord Neuberger's re-wording crucially shifts the focus away from assessing the invention as set out in the claims towards identifying the inventive concept of the patent.

The second question

"Would it be obvious to the person skilled in the art, reading the patent at the priority date, but knowing that the variant achieves substantially the same result as the invention, that it does so in substantially the same way as the invention?"

Lord Neuberger said that the question should be asked on the assumption that the notional addressee knows that the variant works to the extent that it actually does work. This, said Lord Neuberger, is a fair basis on which to proceed in terms of balancing the factors identified in article 1 of the Protocol ( which is reproduced in our introductory article here), consistent with the approach of the German, Italian and Dutch courts, and also consistent with the fact that the notional addressee is told (in the patent itself) what the invention does.

Compared with the original second Improver question, this is a lowering of the burden on the patentee seeking to establish infringement. In the original question, it was a requirement (for the patentee seeking to establish infringement) that it would have been obvious, at the date of publication of the patent to a reader skilled in the art, "that the variant had no material effect". This required the addressee to figure out for himself whether the variant would work.

The facts of the present case illustrated why this was too strict a test: because a chemist would not be able to predict the effect of a substitution for the sodium counter-ion without testing at least the solubility of the active ingredient in the Actavis products, it was not possible to predict in advance whether any particular counter-ion would work. Therefore the case on infringement fell at the original second Improver question. However, salt screening was a routine exercise in determining suitability, and the chemist would be reasonably confident that he would come up with a substitute for the sodium counter-ion. In those circumstances, given that the inventive concept of the patent was the manufacture of a medicament which enabled the pemetrexed anion to be administered with vitamin B12, the application of the second Improver question failed to accord "a fair protection for the patent proprietor" as required by article 1 of the Protocol.

Lord Neuberger said that the reformulated second question should also apply to variants which rely on, or are based on, developments that have occurred since the priority date, even though the skilled addressee is treated as considering the second question as at the priority date.

There is no requirement for the variant not to be inventive. It may be that the infringer is entitled to a new patent, but that is "no reason why the variant should not infringe the original patent".

The third question

"Would such a reader of the patent have concluded that the patentee nonetheless intended that strict compliance with the literal meaning of the relevant claim(s) of the patent was an essential requirement of the invention?"

Lord Neuberger made a number of points intended to explain how this question should properly be answered.

First, although the language of the claim is important, consideration is not excluded of the specification of the patent and all the knowledge and expertise which the notional addressee is assumed to have.

Second, the fact that the language of the claim does not on any sensible reading cover the variant is not enough to justify holding that the patentee does not satisfy the third question. In other words, the fact that the variant is not within the "normal interpretation" of the claim and so does not infringe pursuant to limb (i) of Lord Neuberger's test, does not prevent the skilled reader of the patent from concluding that the patentee did not intend that strict compliance with the literal meaning of the claim was necessary, and therefore from concluding that the variant infringes pursuant to the doctrine of equivalents. This is common sense; if it were otherwise, it is difficult to imagine any scenario in which the doctrine of equivalents might be found to apply.

Third, it is appropriate to ask whether the component at issue is an "essential" part of the invention, but that is not the same thing as asking if it is an "essential" part of the overall product or process of which the inventive concept is part. In Lord Neuberger's view, in the Improver case, Hoffmann J "may" have wrongly considered the latter question.

Fourth, when one is considering a variant which would have been obvious at the date of infringement rather than at the priority date, it is necessary to imbue the notional addressee with rather more information than he might have had at the priority date.

Limb (ii) infringement in the Actavis v Lilly case

As discussed in our introductory article, Lord Neuberger proceeded to consider whether, in the present case, Actavis' proposed products would infringe Eli Lilly's patent by answering the reformulated Improver questions. His tentative conclusion was that the doctrine of equivalents applied. However before deciding the point conclusively, he turned to the prosecution history.

The law on recourse to the prosecution history in the UK and its impact in the analysis of infringement

In support of its case of non- infringement, Actavis relied upon the prosecution history of the patent. This gave rise to a question of general application: whether, and if so when, is it permissible to have recourse to the prosecution of a patent when considering whether a variant infringes that patent?

Lord Neuberger's conclusion is set out in our introductory article. In short, he said that reference to the prosecution history should be restricted to certain limited cases i.e. (i) when the point at issue is truly unclear if one confines oneself to the specification and claims of the patent and (ii) when it would be contrary to the public interest for the contents of the file to be ignored.

Turning to Eli Lilly's prosecution file, he said that it did not justify departing from the preliminary conclusion that the patent would be infringed, given the specific circumstances surrounding the prosecution history. Indeed, in paragraph 89 he expressed the view that the examiner had been wrong in raising the objections (based on disclosure and clarity, and then extent of protection) following which Eli Lilly had narrowed its claim language to pemetrexed disodium.

Accordingly, Lord Neuberger concluded that the Actavis products would directly infringe Eli Lilly's patent.

The law in France

The doctrine of equivalents in France

The French Intellectual Property Code implements Article 69 (1) of the European Patent Convention (EPC). Article L. 613-2 of the Code provides that "the extent of the protection conferred by a European patent or a European patent application shall be determined by the claims. Nevertheless, the description and drawings shall be used to interpret the claims".

In addition, the guidelines provided by the 2000 Protocol on the Interpretation of Article 69 EPC (the Protocol) state that equivalents should be taken into account when assessing the extent of patent protection. The guidelines have not been transposed into French law but the doctrine of equivalents has been progressively defined by French judges putting into practice the rationale expressed in the Protocol. The courts have held that the application of the doctrine of equivalents cannot result in an excessive protection for the patentee, whereas an infringer should not be able to avoid condemnation by the sole adoption of equivalent means1 .

Under the French doctrine of equivalents, a patent is deemed to have been infringed where a different means is used to perform the same function in order to reach an identical or similar result2. The function is defined as the first technical effect produced by the execution of the claimed means, whereas the result is constituted by the practical advantages achieved by the invention3. For example, a claim to a motorbike helmet with a peg was found to be infringed under the doctrine of equivalents by a motorbike helmet with a slot. This was because the infringing helmet would perform the claimed function i.e, guiding the chinstrap through the rotation, in order to reach the same result, that being to make it follow a trajectory which was not completely round4.

The jurisprudence has consistently stated that when the function of a particular claimed means was not known in the prior art and an alleged infringing means of a different form performs the same function, there is infringement by equivalence5. Conversely, there is no infringement by equivalence if the function of the claimed means is not new, in which case the scope of protection should be limited to the claimed means6.

Would a court in France reach the same conclusion as Lord Neuberger in respect of the French designation of Eli Lilly's patent?

For the reasons explained above, an assessment of the novelty of the function of the claimed means is necessary under the French doctrine of equivalents. In the Actavis v Eli Lilly case, in the context of the French designation of Eli Lilly's patent, there was a disagreement between the English High Court (Patents Court) and the Supreme Court on this issue.

The first instance judge considered that the patent did not reveal a new function stemming from the use of pemetrexed disodium, and, as a consequence, the doctrine of equivalents could not apply. He focused on the fact that pemetrexed was already known at the priority date of the patent as having therapeutic effects on cancerous tumours, even though in practice its use as an anti-cancer drug was precluded because of its damaging and fatal side effects.

In the Supreme Court, Lord Neuberger considered that the function of the patent was actually new. He said that the patent disclosed that pemetrexed disodium, when administered with vitamin B12, "could be used for a function for which it could not previously have been satisfactorily or safely used in practice", that being to treat cancerous tumours without such severe side effects. In other words, the patent constituted an improvement compared to prior art, thus the function of the claimed means was new.

There is little case law in France on the application of the doctrine of equivalents in the pharmaceutical industry, so it is difficult to find guidance on the definition of what is a new function. It is worth mentioning though a decision issued in a case involving a patent covering the manufacturing process of a molecule used in a patented drug - the French Supreme Court held that a means enabling a result to be achieved "that was impossible to obtain in prior art" was new in its function7.

Thus, in the authors' opinion and in light of the aforementioned decision, it appears that the approach taken by Lord Neuberger in respect of the French designation of Eli Lilly's patent, of concluding that the function of the claimed means was new, could be followed by a French judge, who could also conclude that the function of the patent was new and that the doctrine of equivalents should apply. Indeed, French courts could view the patent as performing a new function if, considering the circumstances, it constituted an improvement and an important technical progress having regard to prior art.

However, whether a French court would reach such a conclusion, could be impacted by its consideration of the prosecution history.

The law on recourse to the prosecution history in France and its impact on the analysis of infringement

Lord Neuberger said that "While the French courts appear to be more ready to refer to the prosecution file on issues of interpretation or scope than the German or Dutch courts, it is unclear how much, if any, difference there is in outcome".

In the authors' experience, in practice, where it is invoked by a party, French judges do routinely consider the prosecution history as part of the factual context, both when interpreting the claim language and when considering whether there is infringement pursuant to the doctrine of equivalents. French judges pay particular attention to any narrowing of the claim(s) in order to avoid any conflict with relevant prior art, and to secure the grant of the patent. If the patentee has expressly stated its intent to narrow down the scope of the patent protection and to limit it to the particular means claimed, the extent of protection of the claim can be expected to be limited to the particular claimed means and the doctrine of equivalents would not apply. But such waiver needs to be explicit, express and unambiguous8.

As noted above, in the context of the UK designation, Lord Neuberger did take the prosecution file into consideration. In the specific circumstances of the case, he concluded that the file did not justify departing from his initial view that the patent would be infringed.

However, in a decision issued in 2011, the Paris Court of first instance adopted a different approach. The patent claim in issue had been limited after the EPO examiner expressed a view that proposed wording lacked sufficiency and did not have basis in the specification9. The judge decided that the claim had to be limited in accordance with the amendments made because of the lack of sufficiency emphasized by the examiner.

Therefore, when considering whether to cast aside the doctrine of equivalents, French courts do not necessarily distinguish between the different reasons justifying the limitation of the claim.

However when considering whether the Actavis products would infringe the French designation of Eli Lilly's patent, Lord Neuberger did not consider whether the French court would take a different approach to the consideration of the prosecution file.

It therefore seems at least possible that in the Actavis v Eli Lilly dispute, a French judge might have limited the extent of protection of the patent to the combination of pemetrexed disodium with vitamin B12 because of the limitations implemented during the examination process, and, in the end, refused to conclude that the Actavis product constituted an infringement by equivalence of Eli Lilly's patent.

The law in Germany

The legislation governing the "scope of protection" of a patent in Germany (both German patents and European patents granted for Germany) is section14 of the German Patent Act (PatG), which reads as follows.

"The extent of the protection conferred by the patent and the patent application shall be determined by the patent claims. Nevertheless, the description and the drawings shall be used to interpret the patent claims."

When applying s.14 PatG, Art. 69 EPC also has to be considered because it is materially identical with s.14 PatG.

The doctrine of equivalents in Germany

The possibility of patent infringement beyond the literal wording of a granted patent claim, equivalent patent infringement, is a well-established legal concept in patent litigation proceedings before German courts. The requirements which have to be fulfilled are laid down in case law, in particular in the decision "Cutting-Blade I" (file No. X ZR 168/00) of the Federal Supreme Court (Bundesgerichtshof, (BGH)). These requirements are:

  1. Does the modified means realised by the infringing embodiment have objectively the same effect as the means specified in the claim? (same effect)
  2. Would the person skilled in the art, using the common general knowledge, have realised at the priority date that the variant has the same effect? (obviousness)
  3. Are the considerations which the skilled person takes into account for the variant in the light of the meaning of the invention close enough to the considerations taken into account for the literal solution protected by the claims, such that the skilled person will consider the variant as a solution which is equivalent to the literal one? (parity)

Since the doctrine of equivalence has a history that goes back to the 1980's, over the years it has been further developed by the Courts, in particular by the BGH.

Would a court in Germany reach the same conclusion as Lord Neuberger in respect of the German designation of Eli Lilly's patent?

The answer is yes and no, and this ambivalent answer stems from the history of the Actavis v Eli Lilly proceedings in Germany.

In short, on 3 April 2014, the District Court Düsseldorf concluded that Actavis' proposed cancer medicament containing pemetrexed dipotassium and vitamin B12 for inhibiting tumour growth would infringe the German designation of Eli Lilly's EP 1 313 508 patent by the doctrine of equivalents. The District Court issued an injunction against Actavis Group PTC ehf and its subsidiary Actavis Deutschland GmbH & Co. KG.

On 5 March 2015, the second instance Higher District Court Düsseldorf (docket no. I-2 U 16/14) reversed the first instance decision. Contrary to the first instance court, the Higher District Court concluded that Actavis' proposed medicament did not fall within the scope of the doctrine of equivalents.

On 14 June 2016, the Federal Supreme Court (Bundesgerichtshof, BGH) (docket no. X ZR 29/15) annulled the judgment of the Higher District Court Düsseldorf and referred the case back to it. The Federal Supreme Court's reasoning included the following:

  • There is difference between the Actavis v Eli Lilly case and former decisions of the BGH (in particular "Okklusionsvorrichtung" and "Diglycidverbindung") in one substantial aspect: Eli Lilly's patent does not disclose two concrete embodiments with only one of them being claimed, but only one relevant concrete - and also claimed - chemical compound, this being pemetrexed disodium (see BGH judgment at para. 55)
  • The Higher District Court was incorrect in ruling that the infringement of Eli Lilly's patent by equivalent means was incompatible with the basic principles set up by the BGH. According to these principles, an embodiment cannot be included in the scope of protection of a patent if the embodiment is not covered by the patent specification (irrespective of the reasons for this) according to the clear wording of the patent specification. This shall even be the case if the embodiment is disclosed or detectable for persons skilled in the art. Further, the BGH points out that a patent infringement with equivalent means is usually denied if the patent specification reveals several possibilities of how a certain technical effect can be achieved but only one of these possibilities has been included in the patent claim.

It is also noteworthy that the Higher District Court's conclusion in its Actavis v Eli Lilly judgment that the disclosure of a category of chemical compounds has the same legal effect as listing all chemical compounds belonging to the category is inconsistent with more recent jurisprudence from the BGH in the decisions "Okklusionsvorrichtung" and "Diglycidverbindung. Pemetrexed dipotassium is not explicitly stated in the patent specification. Also, it is not sufficient that pemetrexed dipotassium is an antifolate belonging to the same category as pemetrexed disodium (see BGH judgment at para. 71)).

The Higher District Court Düsseldorf has not yet rendered a new judgement.

The law on recourse to the prosecution history in Germany and its impact on the analysis of infringement

According to s.14 PatG and Art. 69 EPC, the documents the German courts may refer to when interpreting the claims are (limited to) the patent specification, in particular the description and the drawings. According to the legislation, the prosecution file cannot be referred to even in exceptional cases, and thus it plays no role in determining the "extent of protection" of a patent contemplated in Article 69 ("Schutzbereichsbestimmung" in the German version of the EPC).

However, in the Actavis v Eli Lilly case, the Higher District Court Düsseldorf relied on files from the grant procedure in its interpretation of the patent in dispute, and the Federal Supreme Court rejected Eli Lilly's complaint in this respect. The Federal Supreme Court ruled that according to the case law of the court it is admissible to refer to a statement of the patent applicant as an indication of how the person skilled in the art would construe the subject matter of the claim. However, statements made in the course of prosecution cannot without further justification be used as the sole basis of interpretation.

The Higher District Court Düsseldorf had taken the examiner's view, that the mention of pemetrexed disodium did not disclose the more general term "pemetrexed" (only), as additional confirmation of the conclusion it had reached for other reasons. The Federal Supreme Court did not consider that the Higher District Court had erred in this respect. However this approach stands in contrast with the tentative expression of opinion by Lord Neuberger that the examiner had been wrong.

Comment

Unquestionably, the Supreme Court's decision in Actavis v Eli Lilly plants a doctrine of equivalents firmly within UK patent law. However, Lord Neuberger said that the reformulated Improver questions remain only guidelines, not strict rules, and that they may also sometimes have to be adapted to apply more aptly to the specific facts of a particular case. It is therefore to be expected that the next decade or two will see continual development of the UK doctrine of equivalents, as litigants push the limits of their cases and the lower courts grapple to further define the law.

If and when the Unified Patent Court (UPC) opens, a harmonised approach to the doctrine of equivalents can be expected to emerge. The approach of the UK Supreme Court in the Actavis v Eli Lilly case, considering and drawing upon higher court jurisprudence from a number of key European Patent Convention countries, can be expected to be considered, and it may be seen as indicating the future course of UPC law in the area. The approach taken by the courts in other participating countries, including Germany and France, can be expected to be considered also. But it is not just the substantive law in which a harmonised approach will need to emerge; with a view to minimising forum shopping a harmonised procedural approach will be needed also, in respect of which practice regarding recourse to the prosecution history is an example.

It remains to be seen, however, when the UPC will become operational, and the extent to which national courts will align national patent law in accordance with the developing jurisprudence of the UPC.

Linked with all this are important questions as to the impact of the UK Supreme Court's judgment for patent law and practice in respect of validity, including patent filing strategy. This will be discussed in a forthcoming article.

If you enjoyed this article, you may also enjoy reading Gordon Harris' article Actavis v Eli Lilly - Should We Have Seen It Coming?

Footnotes



1 Emphasized by Lyon Court of First Instance, 13th November 2014, No 07/02964

2 Example: French Supreme Court, commercial chamber, 8th December 2015, No 14-13.751

3 Paris Court of Appeal, 17th May 2016, No 14/10335

4 Paris Court of First Instance, 28th January 2016, No 13/10277

5 For instance: French Supreme Court, commercial chamber, 29th September 2015, No 14-12.430

6 French Supreme Court, commercial chamber, 23rd November 2010, No 09-15.668

7 French Supreme Court, commercial chamber, 26th January 1993, No 90-16.009 and 90-16.991

8 Paris Court of Appeal, 4th section, 4th March 2009, No 07/08437, confirmed by French Supreme Court, 23rd November 2010, No 09-15.668

9 Paris Court of First Instance, 20th September 2011, No 10/02548

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
31 Oct 2017, Seminar, Toronto, Canada

Gowling WLG and ACA Aponix have joined forces to provide a practical session for regulated financial services businesses, putting the legal requirements into context and giving you concrete actions.

1 Nov 2017, Seminar, London, UK

Our next ThinkHouse Foundations session has again taken on board your feedback from the last session which means we are turning our attention to employment, cloud and warranties and liabilities.

2 Nov 2017, Seminar, Toronto, Canada

Our next ThinkHouse Foundations session has again taken on board your feedback from the last session which means we are turning our attention to employment, cloud and warranties and liabilities.

 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.